PACB Earnings Prediction
The chart below shows how PACB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PACB sees a -0.10% change in stock price 10 days leading up to the earnings, and a -2.54% change 10 days following the report. On the earnings day itself, the stock moves by +0.78%. This data can give you a slight idea of what to expect for the next quarter's release.
PACB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
39.97M
-28.23%
10.98%
Gross Margin
15.90%
-48.39%
110.88%
Operating Margin
-157.40%
18.80%
-30.58%
Net Margin
-151.94%
26.54%
-68.43%
EPS
-0.22
-15.38%
-65.62%
No Data Available
PACB Earnings Analysis
Pacific Biosciences of California, Inc. Corporation (PACB.O) Earnings Conference Call
Positive
Revenue Increase and Growth: Total revenue was $40 million, up 11% from the second quarter of 2024 with sequential growth in instrument consumable and service revenue.
Long-Read Sequencing Growth: Total long-read sequencing systems grew quarter-over-quarter as Q3 revenue included 22 Revio systems and 5 Sequel IIe systems.
Consumable Revenue Growth: Consumable revenue of $18.5 million grew 10% year-over-year and 8% from the second quarter of 2024.
Gross Profit Comparison: Non-GAAP gross profit of $13.0 million represented a non-GAAP gross margin of 33% compared to a non-GAAP gross profit of $18.1 million or 32% in the third quarter of last year.
Cash and Investments Decline: We ended the quarter with $471 million in unrestricted cash and investments compared with $631.4 million on December 31, 2023.
Negative
Revenue Decline Analysis: Total revenue was $40 million, down from $55.7 million in the third quarter of 2023.
Insurance Revenue Decline: Insurance revenue in the third quarter was $16.8 million, a decrease of 52% from $34.7 million in the third quarter of 2023 due to lower Revio unit shipments.
Gross Profit Comparison: Non-GAAP gross profit of $13.0 million represented a non-GAAP gross margin of 33%, compared to a non-GAAP gross profit of $18.1 million or 32% in the third quarter of last year.
Operating Expenses Decrease: Non-GAAP operating expenses were $62.4 million in the third quarter of 2024, representing a 31% decrease from non-GAAP operating expenses of $90.9 million in the third quarter of 2023.
Non-GAAP Net Loss Comparison: Non-GAAP net loss was $46.0 million, representing $0.17 per share in the third quarter of 2024 compared to a non-GAAP net loss of $67.9 million representing $0.27 per share in the third quarter of 2023.
PACB FAQs
How does PACB typically perform around its earnings report dates?
Is Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PACB Earning Call Sentiment
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PACB.O
-8.84%Positive
The earnings call reveals mixed signals: revenue growth and reduced expenses are positive, but the insurance revenue drop and non-GAAP net loss are concerning. The debt restructuring with SoftBank is a positive move, reducing debt and extending maturity. The Q&A highlights optimism about new demand and market expansion, but there's caution regarding the high throughput short-read program. Overall, the positive aspects are balanced by the negatives, suggesting a neutral stock price movement over the next two weeks.